Pre-analytic factors and initial biomarker levels in community-acquired pneumonia patients.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4240803)

Published in BMC Anesthesiol on November 15, 2014

Authors

Alexander Kutz1, Eva Grolimund1, Mirjam Christ-Crain2, Robert Thomann3, Claudine Falconnier4, Claus Hoess5, Christoph Henzen6, Werner Zimmerli4, Beat Mueller1, Philipp Schuetz1, ProHOSP Study Group

Author Affiliations

1: University Department of Medicine, Tellstrasse, CH-5001 Kantonsspital Aarau, Switzerland.
2: Department of Internal Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Basel, Basel, Switzerland.
3: Department of Internal Medicine, Bürgerspital Solothurn, Solothurn, Switzerland.
4: Basel University Medical Clinic Liestal, Liestal, Switzerland.
5: Department of Internal Medicine, Kantonsspital Münsterlingen, Münsterlingen, Switzerland.
6: Department of Internal Medicine, Kantonsspital Lucerne, Lucerne, Switzerland.

Articles citing this

Procalcitonin-guided antibiotic treatment in critically ill patients. Langenbecks Arch Surg (2016) 0.76

Articles cited by this

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med (2003) 28.68

A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med (1997) 24.87

Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest (2007) 7.49

Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet (2004) 5.49

Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA (2009) 5.34

Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem (2005) 3.55

Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect (2011) 2.99

Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem (2005) 2.10

The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med (2007) 1.92

Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis (2012) 1.67

Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia. Eur Respir J (2007) 1.65

Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome. Crit Care Med (2012) 1.64

Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest (2010) 1.63

Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur Respir J (2010) 1.57

Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med (1997) 1.54

Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial. Eur Respir J (2013) 1.51

Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J (2007) 1.47

High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol (2002) 1.20

Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care (2010) 1.17

Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis (2011) 1.15

The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol (2001) 1.14

Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res (2007) 1.14

Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J (2008) 1.10

The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med (2000) 1.09

Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J (2012) 1.06

Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease. Eur J Gastroenterol Hepatol (2006) 1.01

Plasma concentrations and clearance of procalcitonin during continuous veno-venous hemofiltration in septic patients. Shock (2001) 1.01

Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis (2013) 0.98

Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA (2013) 0.97

Assessment of inflammatory markers in patients with community-acquired pneumonia--influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. Clin Chim Acta (2010) 0.90

C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia--influence of antibiotic pre-treatment: results from the German competence network CAPNETZ. J Antimicrob Chemother (2009) 0.86

Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. Clin Biochem (2009) 0.83

Elimination of procalcitonin and plasma concentrations during continuous veno-venous haemodiafiltration in septic patients. Eur J Anaesthesiol (2000) 0.77

Articles by these authors

Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA (2009) 5.34

Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest (2010) 1.63

Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care (2010) 1.17

Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol (2014) 0.97

Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia. Clin Chem Lab Med (2015) 0.91

Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives. BMC Pulm Med (2010) 0.88

Predictors for length of hospital stay in patients with community-acquired pneumonia: results from a Swiss multicenter study. BMC Pulm Med (2012) 0.87

Long-term Prognosis in COPD Exacerbation: Role of Biomarkers, Clinical Variables and Exacerbation Type. COPD (2014) 0.84

Hyponatremia and anti-diuretic hormone in Legionnaires' disease. BMC Infect Dis (2013) 0.78

Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: insights into the ProHOSP study. Virulence (2010) 0.78

Effect of hyperglycaemia on inflammatory and stress responses and clinical outcome of pneumonia in non-critical-care inpatients: results from an observational cohort study. Diabetologia (2013) 0.76

The National Early Warning Score (NEWS) for outcome prediction in emergency department patients with community-acquired pneumonia: results from a 6-year prospective cohort study. BMJ Open (2016) 0.75

Admission levels of asymmetric and symmetric dimethylarginine predict long-term outcome in patients with community-acquired pneumonia. Respir Res (2017) 0.75

Time-dependent association of glucocorticoids with adverse outcome in community-acquired pneumonia: a 6-year prospective cohort study. Crit Care (2017) 0.75

Obesity paradox in patients with community-acquired pneumonia: Is inflammation the missing link? Nutrition (2016) 0.75

Gut, microbiota-dependent trimethylamine-N-oxide is associated with long-term all-cause mortality in patients with exacerbated chronic obstructive pulmonary disease. Nutrition (2017) 0.75